Eli Lilly's Erbitux new dosing regimen is approved by the U.S. FDA for head and neck cancer and colorectal cancer
JCO: Tipifarnib is effective for recurrent and/or metastatic head and neck squamous cell carcinoma
The key material "snap the neck", the manufacturing transformation cannot be moved
JCO: Tipifarnib is effective for recurrent and/or metastatic head and neck squamous cell carcinoma
Innovative head and neck cancer therapy that inhibits RAS signaling is recognized as a breakthrough therapy by the FDA
Strengthen the research and development of epoxy resin UHV "neck" supporting materials-Zhang Xin
Lancet oncol: Comparison of two first-line chemotherapy regimens for patients with recurrent/metastatic head and neck squamous cell carcinoma!
Nat Commun: A clinical study of neoadjuvant anti-OX40 therapy (MEDI6469) in the treatment of patients with head and neck squamous cell carcinoma
How much do you know about oral and head and neck cancer? | BMC Select Research
Black swans have hit the pharmaceutical sector hard, with the market value evaporating by more than $150 billion in four days
First-line immunotherapy for head and neck cancer! AstraZenecom anti-PD-L1 therapy Imfinzi (Infinfan) Phase 3 clinical failure!
Welcome to Echemi
